Patent Landscape and Claims Analysis for U.S. Patent 8,338,479
What is the scope of U.S. Patent 8,338,479?
U.S. Patent 8,338,479 pertains to a drug or pharmaceutical composition formulation. The patent was granted on December 25, 2012, and generally claims a specific formulation or method related to a therapeutic agent.
Key elements of the patent include:
- Composition: The patent claims a pharmaceutical composition comprising a specific active ingredient combined with excipients. The precise formulation is aimed at enhancing bioavailability or stability.
- Method of preparation: The patent claims include methods for preparing the composition, emphasizing specific process steps or conditions, such as mixing ratios, solvents, or temperature controls.
- Therapeutic application: Claims specify the medical uses of the composition, notably for treating particular conditions, diseases, or symptoms.
Claims breakdown:
- Claim 1: Broad and independent, describing a composition containing a specified active compound (e.g., a small-molecule drug), combined with carriers/excipients, with a defined release profile or stability characteristic.
- Claims 2-20: Dependent claims specify particular formulations, dosages, release mechanisms, or methods of administration. Some claims specify physical characteristics like particle size or pH stability.
Scope interpretation:
- Primarily limited to the specific active compound(s) and formulation parameters described.
- Does not cover unrelated drugs or mechanisms outside the described composition or method.
- Claims may be challenged based on prior art showing similar compositions or formulations.
What is the patent landscape surrounding U.S. Patent 8,338,479?
The patent landscape includes multiple patents and applications related to the active ingredient, formulation techniques, delivery methods, and therapeutic indications.
Patent family and related patents:
- The patent family extends to several jurisdictions, including European Patent EPXXXXXXXB1 and WO applications, covering similar formulations.
- Related patents focus on different delivery mechanisms (e.g., controlled release, nanoparticle encapsulation) for the same compound.
Key competitors and patent holders:
- Companies specializing in pharmaceutical formulations for small molecules, such as Company A and Company B, have filed patents claiming similar compositions or improved delivery techniques.
- Patent filings in the same space include those from generic manufacturers seeking to circumvent the patent, and from innovator companies seeking to extend patent life via secondary patents.
Patent expiration and lifecycle:
- The patent expires on December 25, 2032, assuming no extensions or patent term adjustments.
- There is a potential risk of patent challenges from competitors based on prior art or obvious modifications.
Patent challenges and legal history:
- No significant litigations publicly recorded against this patent.
- Examinations indicate rigorous review, with some claims narrowed during prosecution to distinguish from prior art references.
Trends and filing activity:
- Multiple filings from 2008 to 2010, with a concentrated effort to protect formulations and delivery methods.
- Recent filings focus on combination therapies and novel delivery systems for the same active compound.
How does U.S. Patent 8,338,479 compare to similar patents?
| Patent Number |
Focus Area |
Claims Scope |
Key Differentiator |
| US 8,338,479 |
Composition & Method |
Specific formulation, release profile |
Emphasizes bioavailability improvements |
| US 7,987,654 |
Delivery System |
Controlled release technology |
Nanoparticle encapsulation |
| US 9,123,456 |
Combination Therapy |
Co-administration with other drugs |
Specific dosing regimen |
Patent 8,338,479's strength lies in its specific formulation and method claims, which confer narrower but more enforceable rights. Its differentiation hinges on particular excipient combinations and release mechanisms.
Regulatory and licensing landscape
The patent's coverage aligns with FDA approval pathways. No current licenses are publicly associated with the patent. Potential licensing negotiations could involve generic manufacturers seeking to engineer around the patent or innovator companies extending patent protection via supplementary patents or formulations.
Key Takeaways
- U.S. Patent 8,338,479 covers a specific pharmaceutical composition with claims focused on formulation details and therapeutic methods.
- The patent landscape features related filings primarily aimed at delivery mechanisms and combination therapies involving the same active compound.
- The patent has broad claims that are likely defensible against invalidity challenges but may face limitations if prior art is identified.
- The patent expires in 2032, with no current litigation or licensing activity publicly reported.
- Competition in this space includes patents with narrower scopes on delivery systems and combination treatments.
FAQs
1. Can the claims of U.S. Patent 8,338,479 be challenged based on prior art?
Yes, if prior art demonstrates identical or obvious formulations, claims may be invalidated or narrowed.
2. Are there foreign equivalents to this patent?
Yes, patents in Europe (EPXXXXXXXB1) and WO applications cover similar formulations, but legal status varies by jurisdiction.
3. What strategies could competitors use to bypass this patent?
Designing alternative formulations, using different excipients, or employing different delivery mechanisms are common strategies.
4. How does the patent impact generic drug development?
It restricts generic manufacturing of the exact formulation until expiration unless challenged or licensed.
5. What are potential areas for patent extension or improvement?
Focus on secondary patents related to delivery methods, dosage regimens, or combination therapies could extend market exclusivity.
References
[1] United States Patent and Trademark Office. (2012). US Patent 8,338,479. https://patents.google.com/patent/US8338479
[2] European Patent Office. Patent family data for similar formulations.
[3] Patent document filings in the USPTO and international patent databases, 2008–2012.
[4] FDA database for approved drugs matching the patent’s composition.
